Acorda Therapeutics' President and CEO Ron Cohen, M.D. Named Ernst & Young Entrepreneur Of The Year(R) 2007 Award Winner in the Metro New York Area.Award Recognizes Entrepreneurial Excellence in Innovation HAWTHORNE, N.Y. -- Acorda Therapeutics (Nasdaq: ACOR ACOR Association of Cancer Online Resources ACOR American Center of Oriental Research ACOR Advanced Certificate in Operational Risk ACOR Assistant Contracting Officer Representative ACOR Actual Cost of Repair ACOR Administrative Contracting Officers Representative ) today announced that Ron Cohen cohen or kohen (Hebrew: “priest”) Jewish priest descended from Zadok (a descendant of Aaron), priest at the First Temple of Jerusalem. The biblical priesthood was hereditary and male. , M.D. received the Ernst & Young Entrepreneur Of The Year([R]) 2007 Award in the Innovation category in the Metro New York Area. The award recognizes outstanding entrepreneurs who are building and leading dynamic, growing businesses. Dr. Cohen was selected by an independent panel of judges Panel of Judges is an indie pop band from Melbourne, Australia. Members
Ron Cohen, M.D., said, "Over the past 12 years, Acorda Therapeutics has grown from an idea into a thriving business that is developing therapies to improve neurological function for people living with MS, spinal cord injury Spinal Cord Injury Definition Spinal cord injury is damage to the spinal cord that causes loss of sensation and motor control. Description Approximately 10,000 new spinal cord injuries (SCIs) occur each year in the United States. and related conditions of the nervous system. Few endeavors are more challenging or rewarding, and our successes to date are due to the great talent and perseverance of all of Acorda's associates. I am proud to accept this honor on behalf of the entire Acorda team." The Ernst & Young Entrepreneur Of The Year awards program honors entrepreneurs who have demonstrated excellence in such areas as innovation, financial performance, and personal commitment to their businesses and communities. "Ernst & Young is pleased to recognize extraordinary business leaders, such as Ron Cohen, and the companies they have built," said Joseph Capparelli, Ernst & Young Entrepreneur Of The Year program director for Metro New York Area. About the Ernst & Young Entrepreneur Of The Year Awards The Entrepreneur Of The Year awards program was created and is produced by professional services firm Ernst & Young LLP LLP - Lower Layer Protocol . As the first award of its kind, the Ernst & Young Entrepreneur Of The Year Award recognizes outstanding entrepreneurs who are building and leading dynamic and growing businesses. The program, which celebrated its 20th anniversary in 2006, honors entrepreneurs through regional, national and global award programs in over 125 cities and 40 countries. Forward Looking Statements This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including Acorda Therapeutics' ability to successfully market and sell Zanaflex Capsules, the risk of unfavorable results from future studies of Fampridine-SR, delays in obtaining or failure to obtain FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approval of Fampridine-SR, competition, the ability to obtain additional financing to support Acorda Therapeutics' operations, unfavorable results from its preclinical programs, and failure to protect its intellectual property or to defend against the intellectual property claims of others. These and other risks are described in greater detail in Acorda Therapeutics' filings with the Securities and Exchange Commission. Acorda Therapeutics may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. Acorda Therapeutics disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release. About Acorda Therapeutics Acorda Therapeutics is a biotechnology company developing therapies for SCI (Scalable Coherent Interface) An IEEE standard for a high-speed bus that uses wire or fiber-optic cable. It can transfer data up to 1GBytes/sec. (hardware) SCI - 1. Scalable Coherent Interface. 2. UART. , MS and related nervous system disorders Nervous system disorders A satisfactory classification of diseases of the nervous system should include not only the type of reaction (congenital malformation, infection, trauma, neoplasm, vascular diseases, and degenerative, metabolic, toxic, or deficiency . The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug for the management of spasticity spasticity /spas·tic·i·ty/ (spas-tis´i-te) the state of being spastic; see spastic (2). spas·tic·i·ty n. 1. A spastic state or condition. 2. Spastic paralysis. . Acorda is conducting Phase 3 trials of Fampridine-SR to evaluate its safety and efficacy in improving walking ability in people with MS. The Company's pipeline includes a number of products in development for the treatment, regeneration and repair of the spinal cord and brain. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion